G - Physics – 01 – N
Patent
G - Physics
01
N
G01N 33/68 (2006.01)
Patent
CA 2751690
The invention relates to methods and reagents for diagnosing and assessing the prognosis of multiple sclerosis. The present invention is based, in part, upon the discovery that anti-glycan antibodies are useful in evaluating the risk of whether clinically isolated syndrome (CIS) patients suggestive of Multiple sclerosis (MS) will have a clinical relapse within, e.g., 24 months. The invention is also based upon the discovery that anti-glycan antibodies are useful for evaluating the risk of CIS patients suggestive of MS to have a rapid disease progression and accumulate disabilities, e.g., permanent disability, within a certain time frame, e.g., 5 years.
La présente invention concerne des procédés et des réactifs pour le diagnostic et l'évaluation du pronostic de la sclérose en plaques. La présente invention repose, en partie, sur la découverte que des anticorps anti-glycannes sont utiles dans l'évaluation du risque permettant de savoir si des patients présentant le syndrome isolé cliniquement suggestif de la sclérose en plaques vont souffrir d'une rechute dans un intervalle, par exemple de 24 mois. L'invention repose également sur la découverte que les anticorps anti-glycannes sont utiles pour l'évaluation du risque de patients présentant le syndrome cliniquement isolé suggestif de la sclérose en plaques de subir une progression rapide de la maladie et accumuler des incapacités dans un intervalle, par exemple de 5 ans.
Dotan Nir
Dukler Avinoam
Yarden Jennifer
Glycominds Ltd.
Mbm Intellectual Property Law Llp
LandOfFree
Method for evaluating risk in multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for evaluating risk in multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for evaluating risk in multiple sclerosis will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1677354